

Special Issue

SARS-CoV-2 Vaccine Impact in Antibody Response

Message from the Guest Editor

Since the beginning of the COVID-19 pandemic, many anti-SARS-CoV-2 vaccine platforms have been developed and used. Today, there are many data regarding anti-SARS-CoV-2 vaccinations in the literature, but many questions remain among them: What is the impact of bivalent vaccines on antibody response? What is the best vaccination schedule to optimize the immune response? Can we define a neutralizing antibody threshold or a protective antibody titer to guide vaccine strategy? What strategies should be adopted in immunocompromised patients in order to improve the vaccine response? What is the effectiveness of new vaccines, such as recombinant protein vaccines or intranasal vaccines? What are the short- and long-term vaccine antibody responses in children? Furthermore, as the pandemic evolves, other questions will arise. For this Special Issue, we invite submissions in the form of original research articles, reviews or brief reports that address these issues and more generally the humoral response to SARS-CoV-2 vaccines.

Guest Editor

Dr. Ilies Benotmane

1. Department of Nephrology and Transplantation, Strasbourg University Hospital, 67200 Strasbourg, France
2. INSERM UMR-S 1109 LabEx TRANSPLANTEX, Strasbourg University, 67000 Strasbourg, France

Deadline for manuscript submissions

closed (31 October 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/162892

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).